Ensysce Biosciences Inc
NASDAQ:ENSC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.842
7.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Ensysce Biosciences Inc
NASDAQ:ENSC
|
3.2m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Ensysce Biosciences Inc
Glance View
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ensysce Biosciences Inc is -245.9%, which is above its 3-year median of -435.5%.
Over the last 3 years, Ensysce Biosciences Inc’s Operating Margin has increased from -734.4% to -245.9%. During this period, it reached a low of -961.5% on Dec 31, 2022 and a high of -89.7% on Jun 30, 2025.